Bristol-Myers Squibb's late stage hepatitis C product has been designated a Breakthrough Therapy Designation by the FDA. The company's investigational DCV Dual Regimen (daclatasvir and asunaprevir ...

Candidates for antiviral therapy include those who are in the immune clearance (hepatitis B e antigen [HBeAg]-positive) or reactivation (HBeAg-negative) phases. Hepatitis B & hepatocellular ...

A greater understanding of predictors of virological response has led to the ability to individualize therapy in chronic HCV infection. Several new antiviral agents specifically targeting HCV are ...

He or she will also need to pass the national physical therapy exam, or NPTE, and obtain a license to practice in the state where he or she intends to work. Physical therapists sometimes choose to ...